Insulin — a century-old medication whose original discoverers famously sold the patent for a symbolic one dollar, explicitly intending it to remain widely accessible — became one of the most visible symbols of U.S. prescription drug pricing dysfunction, with documented cases of patients rationing doses or dying from insulin rationing due to cost. That story has shifted meaningfully in recent years, driven by a combination of policy action and manufacturer response worth understanding in detail.
How Insulin Prices Got So High
Despite insulin's age as a therapeutic class, the specific insulin products in widespread modern use are analog insulins developed and patented far more recently than the original 1920s discovery, and the insulin market for decades operated with essentially three major manufacturers controlling the vast majority of the U.S. market, with limited genuine price competition despite the presence of multiple "competing" products. List prices for widely used insulin products rose dramatically over roughly a decade, even as the actual manufacturing cost of insulin remained comparatively low — a gap that pricing transparency advocates and multiple state and federal investigations scrutinized closely.
The Rebate System's Role
A significant contributor to rising list prices was the pharmacy benefit manager rebate system, in which manufacturers pay substantial rebates to PBMs and insurers in exchange for favorable formulary placement — creating an incentive structure where a higher list price (from which a larger rebate can be negotiated) could actually be more commercially advantageous to a manufacturer than a lower, more transparent price, even though patients paying list price or a percentage-based coinsurance bore the cost of that inflated list price directly.
The Policy Interventions That Followed
Multiple states passed insulin copay cap legislation limiting what insured patients pay out of pocket per month, generally in the $25-35 range, well below what many patients had been paying previously. The Inflation Reduction Act established a federal $35 monthly insulin copay cap specifically for Medicare beneficiaries, addressing a population that had been particularly exposed to high insulin costs under previous Part D benefit design.
Manufacturer List Price Reductions
Facing sustained political pressure, public scrutiny, and the reality of state-level price cap legislation reshaping the commercial landscape, all three major insulin manufacturers announced substantial list price reductions for key insulin products, along with expanded patient assistance programs capping out-of-pocket costs for many patients regardless of insurance status. These voluntary reductions, combined with the policy-driven copay caps, have meaningfully changed what a substantial share of insulin-dependent patients actually pay compared to the peak pricing era.
Where Gaps Remain
Despite genuine progress, patient advocates note the reforms haven't fully resolved every access barrier: uninsured patients without access to manufacturer assistance programs can still face significant costs, biosimilar insulin competition — intended to provide additional structural price competition — has been slower to achieve meaningful market penetration than advocates hoped, and the underlying rebate system dynamics that contributed to the original price escalation remain largely intact for other drug categories beyond insulin specifically.
Conclusion
The insulin pricing story offers a genuinely instructive case study in how sustained public pressure, state-level policy experimentation, and eventually federal action can meaningfully move drug pricing — even for a drug class where structural incentives had pushed prices in the opposite direction for years. Whether similar combined policy and pressure campaigns can replicate that result for other expensive drug categories remains an open and closely watched question.
